Conclusion
heterogenous bronchiectasis, airway hyperresponsiveness
AIRWAY HYPERRESPONSIVENESS, ADVERSE EFFECTS
The use of inhaled medication is well tolerated in the heterogenous bronchiectasis population, without signs of airway hyperresponsiveness after the first dose of inhaled medication. From this observation, it can be concluded that there is no additional value for this advised tolerance test. However, closely monitoring on adverse effects during the first weeks after starting TIS is recommended.In this sub‐analysis from the BATTLE RCT, the use of inhaled medication (TIS or NaCl 0.9%) was evaluated whereby no signs of airway hyperresponsiveness were observed after the first dose. It can be concluded that there is no additional value for this advised tolerance test. However, during study treatment, airway hyperresponsiveness was seen after a mean of 9.2 (SD 13.9) weeks, whereby closely monitoring on adverse/site effects during the first weeks of TIS is recommended.


